公开(公告)号：EP3327146A1

公开(公告)日：2018-05-30

申请号：EP17210720.3

申请日：2013-11-20

申请人： Phadia AB

发明人： EKLUND, Martin ,  GRÖNBERG, Henrik

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： G06F19/18 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57434

摘要： The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.

公开(公告)号：EP2922970B1

公开(公告)日：2018-08-08

申请号：EP13799501.5

申请日：2013-11-20

申请人： Phadia AB

发明人： GRÖNBERG, Henrik ,  EKLUND, Martin

IPC分类号： C12Q1/6886

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/16 ,  G06F19/24

摘要： The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5% of the SNPs can be disregarded.

公开(公告)号：EP2922967B1

公开(公告)日：2018-01-03

申请号：EP13792689.5

申请日：2013-11-20

申请人： Phadia AB

发明人： GRÖNBERG, Henrik ,  EKLUND, Martin

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： G06F19/18 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57434

摘要： The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.

公开(公告)号：EP2922967A1

公开(公告)日：2015-09-30

申请号：EP13792689.5

申请日：2013-11-20

申请人： Phadia AB

发明人： GRÖNBERG, Henrik ,  EKLUND, Martin

IPC分类号： C12Q1/68 ,  G01N33/574

CPC分类号： G06F19/18 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57434

摘要： The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from aggressive prostate cancer. The present invention is particularly applicable only for patients having a body mass index value greater than 25.

摘要翻译： 本发明涉及基因的反弹到检测和各种形式的遗传标记，以及各种形式的蛋白，它们具有潜在效用作为诊断标志物的识别。 通过确定性采矿生物标志物和遗传标记的多个患者样品中的水平，并结合获得gemäß到预定义的公式中的值，有可能确定矿如果可能做了病人从侵略性前列腺癌症。 本发明只用于具有身体质量指数值比25更大的患者尤为适用

公开(公告)号：EP2922970A1

公开(公告)日：2015-09-30

申请号：EP13799501.5

申请日：2013-11-20

申请人： Phadia AB

发明人： GRÖNBERG, Henrik ,  EKLUND, Martin

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/16 ,  G06F19/24

摘要： The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to forecast if it is likely that the prostate cancer patient will require active therapy like radiation therapy or surgery. A method based on a redundantly designed combination of data is disclosed for estimating if prostate cancer is aggressive or indolent. Said method combines SNP data to form a composite value, wherein at least 5% of the SNPs can be disregarded.

摘要翻译： 本发明一般涉及各种形式的遗传标记物的检测和鉴定以及各种形式的蛋白质，其具有潜在的用途作为诊断标记。 通过确定患者样本中的多个生物标志物和遗传标记的水平，并根据预先确定的公式组合获得的值，可以预测前列腺癌患者是否可能需要诸如放射治疗或 手术。 公开了一种基于冗余设计的数据组合的方法，用于估计前列腺癌是否具有侵略性或惰性。 所述方法将SNP数据组合以形成复合值，其中至少5％的SNP可被忽略。

公开(公告)号：EP2850432A2

公开(公告)日：2015-03-25

申请号：EP13727408.0

申请日：2013-05-16

申请人： Phadia AB

发明人： GRÖNBERG, Henrik ,  EKLUND, Martin

IPC分类号： G01N33/574 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57434 ,  G01N2333/96441

摘要： The present invention relates generally to the detection and identification of various forms of genetic markers, and various forms of proteins, which have the potential utility as diagnostic markers. By determining the level of a plurality of biomarkers and genetic markers in a patient sample, and combining the obtained values according to a predefined formula, it is possible to determine if it is likely that the patient suffers from prostate cancer.

摘要翻译： 本发明一般涉及各种形式的遗传标记物的检测和鉴定，以及各种形式的蛋白质，其具有潜在的用途作为诊断标记。 通过确定患者样品中的多个生物标志物和遗传标记的水平，并且根据预定义的公式组合获得的值，可以确定患者是否可能患有前列腺癌。